# Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

> **NCT03014635** · PHASE3 · COMPLETED · sponsor: **Revance Therapeutics, Inc.** · enrollment: 306 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **BIOLOGICAL:** Botulinum Toxins, Type A
- **BIOLOGICAL:** Placebos

## Key facts

- **NCT ID:** NCT03014635
- **Lead sponsor:** Revance Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-05
- **Primary completion:** 2017-11-03
- **Final completion:** 2017-11-03
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2022-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03014635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03014635, "Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03014635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*